FAT1 and breast carcinoma: In addition, CP-10 was tested in two independent palbociclib-resistant breast cancer cell lines with CDK6 copy amplification (MCF-7 CDK6N2) and FAT1 loss (MCF-7 FAT1 CR), where it successfully induced CDK6 degradation and inhibited proliferation.